Watch the Recordings from the NTRKers Patient Summit
On November 9, 2023, the NTRKers hosted the Patient Summit (recordings found here). We were able to bring together patients, advocates, and healthcare providers from around the world. The Summit included over four hours of virtual discussions and interactions around issues of importance to individuals impacted by NTRK gene fusion cancers. This event also recognized the 5th year anniversary of Vitrakvi (larotrectinib) to achieve FDA approval.
The Summit was moderated by Tim Turnham, PhD, Vice President of Client Services for VOZ Advisors, Dr. Amy C. Moore, Vice President of Global Engagements and Patient Partnerships for LUNGevity, and Sandra Montez, RN, Research Manager for Sydney Children’s Hospital.
Session One: Living on a TRK Fusion Inhibitor, comprised of both a patient/caregiver and physician panel conversation about the experience of living with NTRK gene fusion cancer. Just a few of the topics covered included management of side effects and long-term treatment and best practices for administering TRK fusion inhibitors.
Session Two: Current State of Research and Topics for Future Research, included a physician and clinical speaker panel discussion on recent data related to NTRK gene fusion cancer, ongoing clinical trials, and understanding resistance.
We were joined by the following clinical speakers:
- Victor Moreno, MD, PhD, Director of Clinical Research Early Phase Clinical Trials, START Madrid – FJD
- Anthony Conley, MD, Oncologist and Associate Professor, Department of Sarcoma Medical Oncology, MD Anderson
- David Hong, MD, Deputy Chair, Department of Investigational Cancer Therapeutics, MD Anderson
- Herbert Loong, MD, Clinical Associate Professor Department of Clinical Oncology, The Chinese University of Hong Kong
- Fernando Lopez-Rios, MD, PhD, Chief of Molecular Diagnostic Services, Department of Pathology, University Hospital in Madrid, Spain
- Marcia Brose, MD, PhD, Professor, Chief of Cancer Services, and Co-Director of Community Clinical Research, Jefferson Torresdale Hospital
- Vivek Subbiah, MD, Chief of Early-Phase Drug Development, Sarah Cannon Research Institute